<DOC>
	<DOCNO>NCT02411786</DOCNO>
	<brief_summary>The purpose study determine vaccine call pTVG-AR enhance patient ' immune response prostate cancer .</brief_summary>
	<brief_title>A Phase I Study DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain ( AR LBD ) +/-GMCSF</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Patients must least 18 year age histologic diagnosis adenocarcinoma prostate . Patients must metastatic prostate cancer ( clinical stage D1 D2 disease ) , previously document lymph node , soft tissue and/or bone metastasis radiographic imaging ( include CT ( MRI ) abdomen pelvis bone scintigraphy ) . Patients situation reasonable clinical suspicion second primary tumor ( nonprostate cancer reason radiographic abnormality ) eligible unless metastatic disease histologically confirm prostate cancer . Patients must start androgen deprivation therapy ( bilateral orchiectomy versus LHRH agonist , without androgen antagonist ) least one month ( 4 week ) prior enrollment six month ( 24 week ) prior enrollment . Patients must continue androgen deprivation therapy throughout study period , patient permit change type androgen deprivation therapy ( e.g . add androgen antagonist ) course investigational therapy . Patients must serum testosterone &lt; 50 ng/dL demonstrate within 1 month study entry . Patients must either candidate docetaxel chemotherapy newly diagnose metastatic prostate cancer , determine treat oncologist , decline therapy Patients must evidence response androgen deprivation define documented decline serum PSA value preandrogen deprivation treatment baseline without evidence PSA progression androgen deprivation ( define PCWG2 criterion 25 % increase serum PSA absolute increase 2 ng/mL nadir ) . Patients prior history second malignancy eligible provide treated curative intent free disease great three year . There exclusion patient history basal cell carcinoma , squamous cell skin cancer , situ carcinoma adequately treat . Patients sexually active must use reliable form contraception study 4 week last immunization . ECOG performance score &lt; 2 . Patients must adequate hematologic , renal liver function define : WBC &gt; 3000/mm3 , hematocrit &gt; 30 % , platelet count &gt; 100,000/mm3 , serum creatinine &lt; 1.6 mg/dl calculate creatinine clearance &gt; 60 cc/min , serum bilirubin &lt; 2.0 mg/dl , within 4 week prior first immunization . Patients must inform experimental nature study potential risk must sign IRBapproved write informed consent form indicate understanding . Small cell ( nonadenocarcinoma ) variant prostate cancer histology . Patients evidence immunosuppression treat immunosuppressive therapy , chemotherapy , chronic treatment dose corticosteroid ( great equivalent 10 mg prednisone per day ) , radiation therapy &gt; 30 % bone marrow , within 6 month first vaccination . Treatment salvage radiation therapy encompass &lt; 30 % bone marrow must complete 4 week prior first vaccination . Seropositive HIV , hepatitis B ( HBV ) hepatitis C ( HCV ) per patient history . Patients previously treat neoadjuvant and/or adjuvant androgen deprivation ( e.g . radiation therapy ) prior 6month eligibility period allow , assume meet criterion progression ( define PCWG2 criterion 25 % increase serum PSA absolute increase 2 ng/mL nadir ) treatment . Patients must concurrently take medication supplement know hormonal effect ( LHRH agonists nonsteroidal antiandrogen ) , include PCSPES , megestrol acetate , finasteride , ketoconazole , estradiol , Saw Palmetto . All medication possible anticancer effect must discuss Protocol Principal Investigator prior study entry . Patients previously treat herbal supplement describe 6.B.5 , potential experimental therapy prostate cancer ( apart LHRH agonists antiandrogens describe 6.A.3 ) , must discontinue treatment complete least onemonth washout prior first vaccination . Patients must plan receive concomitant chemotherapy , biological immune therapy , radiation therapy treatment prostate cancer period study treatment . Patients must know psychological sociological condition , addictive disorder family problem , would preclude compliance protocol . Patients must know allergic reaction GMCSF tetanus vaccine . Prior treatment another experimental antitumor vaccine permissible . Patients unstable severe intercurrent medical condition laboratory abnormality would impart , judgment Protocol Principal Investigator , excess risk associate study participation study agent administration . Unable unwilling undergo two leukapheresis procedure . Patients medical condition preclude leukapheresis . Patients concurrent enrollment phase I , II , III investigational treatment study treatment prostate cancer .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>